CJC-1295 / Ipamorelin - Growth-hormone-pathway recovery support blend

Treatment is determined by a licensed clinician after review. Not all patients are candidates. Individual results vary.

About CJC-1295 / Ipamorelin

What it is, how it works, what it's studied for, and safety considerations.

What Is CJC-1295 / Ipamorelin?

CJC-1295 + Ipamorelin is a peptide combination commonly discussed in wellness settings for growth-hormone-pathway support. CJC-1295 is a long-acting growth hormone–releasing hormone (GHRH) analog studied for GH/IGF-1 stimulation. Ipamorelin is a selective growth hormone secretagogue/ghrelin-receptor agonist studied for GH release. This combination is not an FDA-approved branded therapy for general wellness, muscle growth, anti-aging, or recovery.

How It Works

CJC-1295 is intended to stimulate the GHRH pathway, while ipamorelin acts through the growth hormone secretagogue receptor. The goal of the combination is to support pulsatile growth hormone signaling without directly administering growth hormone. Clinical evidence for broad wellness, anti-aging, muscle, and recovery claims is limited; benefits are framed as provider-considered support rather than guaranteed outcomes.

What It’s Studied For

CJC-1295 has been studied in healthy adults for pharmacokinetic and pharmacodynamic effects on GH and IGF-1. Ipamorelin has preclinical and pharmacologic research showing selective GH secretagogue activity. The combination has far less rigorous human outcome data than FDA-approved medications, and FDA has identified safety concerns for compounded CJC-1295 and ipamorelin-related substances.

How It May Be Used in a Clinician-Supervised Program

A licensed clinician may consider this option for patients seeking recovery-support or growth-hormone-pathway support when medically appropriate. Review may include cancer history, diabetes/glucose status, edema/fluid-retention history, sleep apnea, cardiovascular risk, IGF-1 concerns, medication list, and goals.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Average starting option

3 mL

Available options

3 mL
5 mL

Provider note: Do not change dose, frequency, or route of use unless directed by your clinician.

Safety Considerations

Possible injection-site reactions, headache, flushing, water retention, and numbness/tingling.
Changes in glucose metabolism and theoretical risks from chronically elevated IGF-1.
Concerns about peptide purity and impurities in compounded or non-approved products.
FDA has flagged CJC-1295 and ipamorelin acetate for safety and peptide-characterization concerns.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions

Is CJC-1295 / Ipamorelin guaranteed to be prescribed?

No. Prescriptions are never guaranteed. A licensed clinician reviews your medical intake and determines whether treatment is medically appropriate.

Can my provider change my treatment or dose?

Yes. Your selected treatment and preferred starting option are treated as preferences. Your provider may approve your selection, recommend a different option, adjust dosing, request more information, or deny treatment.

Does payment guarantee treatment?

No. Payment does not guarantee approval, a prescription, a specific medication, or a specific dose.

How is CJC-1295 / Ipamorelin used?

Use instructions are provided only if treatment is prescribed. If prescribed, follow your clinician's dosing and administration instructions exactly.

Are compounded medications FDA-approved?

No. Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved and are not evaluated by FDA for safety, effectiveness, or quality before marketing.

What comes with injectable treatments if prescribed?

When prescribed by a licensed clinician, injectable peptide treatments may ship with syringes, prep pads for sterilization, and an instructions and dosing guide. Use only as directed by your clinician.

Disclaimer

Although the information on this page is based on available educational research and product information, it is provided for informational purposes only and is not medical advice. Treatment decisions, medication selection, dosing, and eligibility are determined by a licensed clinician after review. Not all patients are candidates, and individual results may vary. Use medications only as directed by your clinician.